Volta Labs and Twist Bioscience push target enrichment closer to walk-away automation
Read how Volta Labs’ Twist Fast Hyb launch on Callisto could reshape automated NGS target enrichment, lab throughput and sequencing workflows.
Read how Volta Labs’ Twist Fast Hyb launch on Callisto could reshape automated NGS target enrichment, lab throughput and sequencing workflows.
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Watchmaker Genomics is repurposing CRISPR-Cas9 to streamline NGS normalization. Find out why this matters for sequencing at scale.